New Monoclonal Antibody Shows Promise for Rare Liver Disease PSC

A new monoclonal antibody, nebokitug, has shown promising safety and efficacy in treating Primary Sclerosing Cholangitis (PSC), a rare and severe liver disease. Initial trials revealed its potential to significantly reduce liver inflammation and fibrosis, offering hope where current treatments are limited to liver transplantation.

• Nebokitug antibody demonstrated safety and efficacy in Phase 2 trials.
• Treatment aims to reduce inflammation and fibrosis in bile ducts.
• Study led by UC Davis Health and published in a leading gastroenterology journal.
• Offers significant hope for Primary Sclerosing Cholangitis (PSC) patients.
• PSC is a chronic liver disease with no approved drug therapy currently.
• Results pave the way for a pivotal Phase 3 clinical study.

Read the full story on Quick Digest.